MedTrace Logo

The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle

NCT01799850 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-02-27

No results posted yet for this study

Summary

Subjects with type 2 diabetes will be treated with Actos or placebo for eight weeks and needle biopsies of muscle will quantify changes in any of seven different glucose transport proteins in muscle.

Conditions

  • Diabetes Type 2

Interventions

DRUG

Pioglitazone

pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned

DRUG

placebo

placebo assigned randomly, double blind

Sponsors & Collaborators

  • Takeda Pharmaceuticals North America, Inc.

    collaborator INDUSTRY

  • East Tennessee State University

    lead OTHER

Principal Investigators

  • Charles A Stuart, MD · ETSU Quillen College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2004-03-31
Completion
2004-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01799850 on ClinicalTrials.gov